POTENTIAL ANGIOPREVENTIVE AGENT OF BENZOQUINONOID COMPUND FROM ARDISIA CRISPA ROOT IN VITRO AND IN VIVO

Ardisia crispa (Thunb) A.DC is a local medicinal plant traditionally claimed for its therapeutic use in various inflammatory-related diseases. Its root part has been scientifically validated to be effective in various inflammatory animal models. In this study, we isolated its bioactive compound (AC2) from the hexane fractionated extract of the plant's root (ACRH) and tested its antiangiogenic properties against human umbilical vein endothelial cells (HUVECs) and zebra fish assay, respectively. Our findings exhibited promising antiangiogenic effects of both AC2 and ACRH by suppressing its angiogenic signaling cascades, in vitro as well as significantly inhibited zebrafish embryo intersegmental vessels (ISVs), confirming its antiangiogenic role

URL Reference:

PUBLICATION

JOURNAL
Title : Ardisia crispa root hexane fraction suppressed angiogenesis in human umbilical vein endothelial cells (HUVECs) and in vivo zebrafish embryo model
Description :
Ardisia crispa Thunb. A. DC. (Primulaceae) has been used extensively as folk-lore medicine in South East Asia including China and Japan to treat various inflammatory related diseases. Ardisia crispa root hexane fraction (ACRH) has been thoroughly studied by our group and it has been shown to exhibit anti-inflammatory, antihyperalgesic, anti-arthritic, anti-ulcer, chemoprevention and suppression against inflammation-induced angiogenesis in various animal model. Nevertheless, its effect against human endothelial cells in vitro has not been reported yet. Hence, the aim of the study is to investigate the potential antiangiogenic property of ACRH in human umbilical vein endothelial cells (HUVECs) and zebrafish embryo model. ACRH was separated from the crude ethanolic extract of the plant’s root in prior to experimental studies. MTT assay revealed that ACRH exerted a concentration-dependent antiproliferative effect on HUVEC with the IC50 of 2.49 ± 0.04 μg/mL. At higher concentration (10 μg/mL), apoptosis was induced without affecting the cell cycle distribution. Angiogenic properties including migration, invasion and differentiation of HUVECs, evaluated via wound healing, trans-well invasion and tube formation assay respectively, were significantly suppressed by ACRH in a concentrationdependent manner. Noteworthily, significant antiangiogenic effects were observed even at the lowest concentration used (0.1 μg/mL). Expression of proMMP-2, vascular endothelial growth factor (VEGF)-C, VEGF-D, Angiopoietin-2, fibroblast growth factor (FGF)-1, FGF-2, Follistatin, and hepatocyte growth factor (HGF) were significantly reduced in various degrees by ACRH. The ISV formation in zebrafish embryo was significantly suppressed by ACRH at the concentration of 5 μg/mL. These findings revealed the potential of ACRH as antiangiogenic agent by suppressing multiple proangiogenic proteins. Thus, it can be further verified via the transcription of these proteins from their respective DNA, in elucidating their exact pathways.
Authors :
Date Publish : 04/09/2019
BOOK
BOOK CHAPTER

DATASET SOURCES

NO FILE IN THIS PROJECT